The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study

Overview of attention for article published in Targeted Oncology, April 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 1,628 followers.

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. https://t.co/EeoQlZxrUB

13 Apr 2018

Reply Repost Favourite

RT @FlorianSlimano: Confirmation that acid-reducing agents have no impact on effectiveness of vemurafenib https://t.co/WOMLYRLqWH

13 Apr 2018

Reply Repost Favourite

Confirmation that acid-reducing agents have no impact on effectiveness of vemurafenib https://t.co/WOMLYRLqWH

13 Apr 2018

Reply Repost Favourite

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma https://t.co/ThHW9v1fZq https://t.co/N2Vo4ugW9f

12 Apr 2018

Reply Repost Favourite